AVL-292 is a selective, orally administered, inhibitor of Bruton’s tyrosine kinase (Btk). The expression of Btk is found on B-lymphocytes and has been implicated in the growth and survival of certain B-cell lymphomas as well as in CLL. This is a Phase Ib, escalating dose study of AVL-292 as a monotherapy in subjects with relapsed and/or refractory B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia, and Waldenstrom’s macroglobulinemia
IMGN 529 consists of CD37 targeting humanized monoclonal antibody and cytotoxic maytansinoid DM1. In this Phase I study IMGN529 is administered intravenously every 3 weeks to patients with relapsed or refractory Non-Hodgkin’s lymphoma.